BioCentury
ARTICLE | Clinical News

OC459: Phase II started

December 9, 2013 8:00 AM UTC

Atopix began a double-blind, placebo-controlled, European Phase II trial to evaluate once-daily oral OC459 for 6 months. The trial is funded by an £1.7 million ($2.8 million) grant from the U.K. Biome...